|Mr. Sheldon L. Koenig||Pres, CEO & Director||507.64k||N/A||1966|
|Mr. Richard B. Bartram||CFO & Corp. Sec.||529.75k||N/A||1982|
|Dr. Kenneth J. Fiorelli||Chief Technical Operations Officer||N/A||N/A||N/A|
|Mr. Benjamin Church||Head of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Mr. Keith F. Lenden||VP of Corp. Devel. & Strategy||N/A||N/A||1973|
|Renee Marotta||Head of Marketing||N/A||N/A||N/A|
|Dr. Joanne Micale Foody FACC, M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Ms. April Seiler||Sr. Director of Project Management||N/A||N/A||N/A|
|Roberta Peterson||Sr. Director of National Accounts||N/A||N/A||N/A|
|Mr. Jerry Penn||Exec. Director of Managed Care||N/A||N/A||N/A|
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics, Inc.’s ISS governance QualityScore as of 1 July 2021 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 8.